• Wenwen Sun, Yuling Xing, Dexian Kong, Zhimin Zhang, Huijuan Ma, and Linlin Yang.
• North China University of Science and Technology, 21 Bohai Dadao, Caofeidian District, Tangshan, Hebei 063210, China.
• Medicine (Baltimore). 2022 Sep 23; 101 (38): e30553e30553.

BackgroundAs novel hypoglycemic drugs, the effects of sodium-dependent glucose transporter 2 inhibitors (SGLT-2I) on inflammatory factors such as C-reactive protein (CRP) remain unclear.MethodsWe conducted a meta-analysis of studies on SGLT-2I in the treatment of type 2 diabetes (T2DM) to observe the changes of CRP in patients with T2DM. We searched 4 electronic databases (CNKI, PubMed, EMBASE, and Cochrane Library) for articles published up to December 31, 2021. Studies were analyzed using a random-effects model to obtain standard deviation mean differences (SMDs) and 95% confidence intervals (CIs). Sensitivity and subgroup analyses were performed. Publication bias was evaluated using funnel plots and Egger test.ResultsWe included data from 927 patients in 13 confirmatory trials that showed a significant decrease in CRP among patients with T2DM treated with SGLT-2I. The decrease was more significant with than without SGLT-2I. In subgroup analysis according to nationality, medication, and comorbidities, CRP reduction was associated with nationality, SGLT-2I type, and the presence of comorbidities. Sensitivity analysis showed that our results were reliable and found no evidence of substantial publication bias.ConclusionsSGLT-2I could reduce CRP levels in patients with T2DM.RegistrationInternational Prospective Register for Systematic Reviews (PROSPERO) number CRD42021268079.Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.

22 keywords...

hide…